Erysipelas associated with recurrent squamous cell carcinoma of the labium majus after radiochemotherapy

被引:0
|
作者
Barbach, Younes [1 ]
Zahra Mernissi, Fatima [1 ]
机构
[1] Hop Univ Hassan II, Serv Dermatol & Venerol, Fes, Morocco
来源
PAN AFRICAN MEDICAL JOURNAL | 2019年 / 33卷
关键词
Epidermoid carcinoma; radiochimiotherapy; erysipelas; recurrent;
D O I
10.11604/pamj.2019.33.248.16771
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The erysipelas is a bacterial infection most frequently due to (85% of cases) streptococcus β-hemolytic of group A (SGA), resulting in non-necrotizing dermo-hypodermitis. Many factors may play a role in its occurrence such as general factors: diabetes, immunosuppression, chemotherapy, radiotherapy as well as locoregional ports of entry such as leg ulcer, an insect bite, intertrigo. The occurrence of erysipelas associated with recurrent squamous cell carcinoma after radiochemotherapy is exceptional, requiring early treatment of dermo-hypodermitis as well as suitable and multidisciplinary management of the carcinoma. The mechanism of the occurrence of erysipelas after radiotherapy coincides with its pathophysiology. Indeed, this therapeutic component, which is very used to treat squamous cell carcinoma, alters lymphatic drainage resulting, very gradually, in lymph fibrosis thus weakening the defense mechanism. Its association with alteration of cellular immunity, also favored by radiotherapy and chemotherapy, can cause the occurrence of erysipelas in these patients. We report the case of a 50-year old female patient with a 1-year history of squamous cell carcinoma of the right labium majus treatment with radiochemotherapy with remission. Eight months later, the patient had recurrence. Evolution was marked by the appearance of a painful hot erythematous plaque on the right thigh suggesting erysipelas, confirmed by laboratory tests which showed an infection. The patient was put on antibiotic therapy with good improvement and then referred to the Department of Oncology for recurrence management. © Younes Barbach et al.
引用
收藏
页数:2
相关论文
共 50 条
  • [21] A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    de Souza, Jonas A.
    Davis, Darren W.
    Zhang, Yujian
    Khattri, Arun
    Seiwert, Tanguy Y.
    Aktolga, Serdal
    Wong, Stuart J.
    Kozloff, Mark F.
    Nattam, Sreenivasa
    Lingen, Mark W.
    Kunnavakkam, Rangesh
    Stenson, Kerstin M.
    Blair, Elizabeth A.
    Bozeman, Jeffrey
    Dancey, Janet E.
    Vokes, Everett E.
    Cohen, Ezra E. W.
    CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2336 - 2343
  • [22] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Bernier, Jacques
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 705 - 713
  • [23] Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal
    Wright, Jean L.
    Gollub, Marc J.
    Weiser, Martin R.
    Saltz, Leonard B.
    Wong, W. Douglas
    Paty, Philip B.
    Temple, Larissa K.
    Guillem, Jose G.
    Minsky, Bruce D.
    Goodman, Karyn A.
    DISEASES OF THE COLON & RECTUM, 2011, 54 (09) : 1090 - 1097
  • [24] Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma
    Peron, Julien
    Ceruse, Philippe
    Lavergne, Emilie
    Buiret, Guillaume
    Bich-Nga Pham
    Chabaud, Sylvie
    Favier, Bertrand
    Girodet, Didier
    Zrounba, Philippe
    Ramade, Antoine
    Fayette, Jerome
    ANTI-CANCER DRUGS, 2012, 23 (09) : 996 - 1001
  • [25] Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma
    Pestana, Roberto Carmagnani
    Becnel, Melody
    Rubin, Maria Laura
    Torman, Danice K.
    Crespo, James
    Phan, Jack
    Hanna, Ehab
    Bell, Diana
    Glisson, Bonnie S.
    Johnson, Jason M.
    Lee, J. Jack
    Ferrarotto, Renata
    ORAL ONCOLOGY, 2020, 101
  • [26] Risk Factors for Hemorrhage After Chemoradiation for Oropharyngeal Squamous Cell Carcinoma
    Self, Elizabeth M.
    Bumpous, Jeffrey
    Ziegler, Craig
    Wilson, Liz
    Potts, Kevin
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2013, 139 (04) : 356 - 361
  • [27] Recurrent squamous-cell carcinoma of the head and neck: Overview of current therapy and future prospects
    Ganly, I
    Kaye, SB
    ANNALS OF ONCOLOGY, 2000, 11 (01) : 11 - 16
  • [28] Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Alkhatib, Hosam H.
    Maroun, Christopher A.
    Guller, Meytal
    Cooper, Dylan J.
    Wu, Evan S.
    Eisele, David W.
    Fakhry, Carole
    Pardoll, Drew
    Seiwert, Tanguy Y.
    Zhu, Gangcai
    Mandal, Rajarsi
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 170 (03) : 828 - 836
  • [29] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [30] Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    El Rassy, Elie
    Assi, Tarek
    Bakouny, Ziad
    El Karak, Fadi
    Pavlidis, Nicholas
    Ghosn, Marwan
    FUTURE ONCOLOGY, 2019, 15 (08) : 909 - 924